Read by QxMD icon Read

Schizophrenia related ds

shared collection
12 papers 25 to 100 followers Schizophrenia and related psychotic ds
By Ahmed Elaghoury Egyptian board certified in psychiatry. Combined practice with neurology and sleep medicine.
John M Kane, Ofer Agid, Marjorie L Baldwin, Oliver Howes, Jean-Pierre Lindenmayer, Stephen Marder, Mark Olfson, Steven G Potkin, Christoph U Correll
Treatment-resistant schizophrenia (TRS) occurs in approximately 30% of individuals diagnosed with schizophrenia. The identification and management of TRS in clinical practice are inconsistent and not evidence based. No established clinically relevant criteria for defining and treating TRS exist, although guidelines have been promulgated for clozapine use among TRS patients. This report summarizes the consensus from a roundtable that focused on defining and identifying TRS, pathways to treatment resistance, current treatments, unmet needs, and disease burden...
March 5, 2019: Journal of Clinical Psychiatry
Jari Tiihonen, Heidi Taipale, Juha Mehtälä, Pia Vattulainen, Christoph U Correll, Antti Tanskanen
Importance: The effectiveness of antipsychotic polypharmacy in schizophrenia relapse prevention is controversial, and use of multiple agents is generally believed to impair physical well-being. Objective: To study the association of specific antipsychotic combinations with psychiatric rehospitalization. Design, Setting, and Participants: In this nationwide cohort study, the risk of psychiatric rehospitalization was used as a marker for relapse among 62 250 patients with schizophrenia during the use of 29 different antipsychotic monotherapy and polypharmacy types between January 1, 1996, and December 31, 2015, in a comprehensive, nationwide cohort in Finland...
February 20, 2019: JAMA Psychiatry
Christoph U Correll, Jennifer Kern Sliwa, Dean M Najarian, Stephen R Saklad
With more long-acting injectable (LAI) antipsychotics available for treating schizophrenia, each with variable durations of action (2 weeks to 3 months), it is important to have clear management strategies for patients developing breakthrough psychotic symptoms or experiencing symptomatic worsening on LAIs. However, no treatment guidelines or clinical practice pathways exist; health-care providers must rely on their own clinical judgment to manage these patients. This article provides practical recommendations-based on a framework of clinical, pharmacokinetic, and dosing considerations-to guide clinicians' decisions regarding management of breakthrough psychotic symptoms...
December 27, 2018: CNS Spectrums
Oren Tene, Mayanit Sigler, Roni Shiloh, Abraham Weizman, Dov Aizenberg
The clock-drawing test (CDT) is used widely to evaluate cognitive disorders, but its role in the assessment of psychotic disorders has not been studied. We sought to examine whether the CDT plays a role as an indicator of psychosis and to establish its sensitivity to clinical improvement of psychosis. The CDT was administered twice to 53 hospitalized patients without dementia but with psychosis: once at admission and again before discharge. The CDT scores were calculated in a random order by two independent senior psychiatrists who were blinded to the patients' status (admission or discharge)...
May 2016: International Clinical Psychopharmacology
Mathew Chiang, Radhika Natarajan, Xiaoduo Fan
Vitamin D (vitD) is known for its essential role in calcium homeostasis and bone health. VitD is made endogenously in the skin from UVB radiation from sunlight. VitD is now considered as a potent neurosteroid hormone, critical to brain development and normal brain function, and is known for its anti-inflammatory property affecting various aspects of human health. VitD ligand-receptor, a receptor that mediates much of vitD's biological actions, has been found throughout the body including the central nervous system...
February 2016: Evidence-based Mental Health
Dorothy Y Y Tang, Amy C Y Liu, Simon S Y Lui, Bess Y H Lam, Bonnie W M Siu, Tatia M C Lee, Eric F C Cheung
Impairment in facial emotion perception is believed to be associated with aggression. Schizophrenia patients with antisocial features are more impaired in facial emotion perception than their counterparts without these features. However, previous studies did not define the comorbidity of antisocial personality disorder (ASPD) using stringent criteria. We recruited 30 participants with dual diagnoses of ASPD and schizophrenia, 30 participants with schizophrenia and 30 controls. We employed the Facial Emotional Recognition paradigm to measure facial emotion perception, and administered a battery of neurocognitive tests...
February 28, 2016: Psychiatry Research
Derri L Shtasel, Oliver Freudenreich, Travis P Baggett
Presentation of Case. Dr. Alex S. Keuroghlian (Psychiatry): A 40-year-old woman with a history of psychosis was admitted to this hospital from a homeless shelter because of headache and hypertension. One week before admission, the patient had accepted placement in a homeless shelter, after spending..
December 24, 2015: New England Journal of Medicine
Stefan Leucht, Myrto Samara, Stephan Heres, Maxine X Patel, Toshi Furukawa, Andrea Cipriani, John Geddes, John M Davis
BACKGROUND: The concept of dose equivalence is important for many purposes. The classical approach published by Davis in 1974 subsequently dominated textbooks for several decades. It was based on the assumption that the mean doses found in flexible-dose trials reflect the average optimum dose which can be used for the calculation of dose equivalence. We are the first to apply the method to second-generation antipsychotics. METHODS: We searched for randomized, double-blind, flexible-dose trials in acutely ill patients with schizophrenia that examined 13 oral second-generation antipsychotics, haloperidol, and chlorpromazine (last search June 2014)...
November 2015: Schizophrenia Bulletin
Peter Fonagy
This paper provides a comprehensive review of outcome studies and meta-analyses of effectiveness studies of psychodynamic therapy (PDT) for the major categories of mental disorders. Comparisons with inactive controls (waitlist, treatment as usual and placebo) generally but by no means invariably show PDT to be effective for depression, some anxiety disorders, eating disorders and somatic disorders. There is little evidence to support its implementation for post-traumatic stress disorder, obsessive-compulsive disorder, bulimia nervosa, cocaine dependence or psychosis...
June 2015: World Psychiatry: Official Journal of the World Psychiatric Association (WPA)
Myrto T Samara, Claudia Leucht, Mariska M Leeflang, Ion-George Anghelescu, Young-Chul Chung, Benedicto Crespo-Facorro, Helio Elkis, Kotaro Hatta, Ina Giegling, John M Kane, Monica Kayo, Martin Lambert, Ching-Hua Lin, Hans-Jürgen Möller, José María Pelayo-Terán, Michael Riedel, Dan Rujescu, Benno G Schimmelmann, Alessandro Serretti, Christoph U Correll, Stefan Leucht
OBJECTIVE: How long clinicians should wait before considering an antipsychotic ineffective and changing treatment in schizophrenia is an unresolved clinical question. Guidelines differ substantially in this regard. The authors conducted a diagnostic test meta-analysis using mostly individual patient data to assess whether lack of improvement at week 2 predicts later nonresponse. METHOD: The search included EMBASE, MEDLINE, BIOSIS, PsycINFO, Cochrane Library, CINAHL, and reference lists of relevant articles, supplemented by requests to authors of all relevant studies...
July 2015: American Journal of Psychiatry
Seiya Miyamoto, L Fredrik Jarskog, W Wolfgang Fleischhacker
Schizophrenia for many patients is a lifelong mental disorder with significant consequences on most functional domains. One fifth to one third of patients with schizophrenia experience persistent psychotic symptoms despite adequate trials of antipsychotic treatment, and are considered to have treatment-resistant schizophrenia (TRS). Clozapine is the only medication to demonstrate efficacy for psychotic symptoms in such patients. However, clozapine is not effective in 40%-70% of patients with TRS and it has significant limitations in terms of potentially life-threatening side effects and the associated monitoring...
November 2014: Journal of Psychiatric Research
Zvezdana Stojanović, Zeljko Spirić
INTRODUCTION: Neuroleptic malignant syndrome is rare, but potentially fatal idiosyncratic reaction to antipsychotic medications. It is sometimes difficult to diagnose some clinical cases as neuroleptic malignant syndrome and differentiate it from the acute viral encephalitis. CASE REPORT: We reported a patient diagnosed with acute psychotic reaction which appeared for the first time. The treatment started with typical antipsychotic, which led to febrility. The clinical presentation of the patient was characterised by the signs and symptoms that might have indicated the neuroleptic malignant syndrome as well as central nervous system viral disease...
June 2014: Vojnosanitetski Pregled. Military-medical and Pharmaceutical Review
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"